Healthcare
Live Price
Offline$4.66
+0.00% today
Window Change
-13.70%
Window
Jun 23, 2025 → Jan 6, 2026
Historical coverage is still expanding
This 1Y daily history view is usable, but not fully loaded yet. Additional bars will appear as backfills continue.
Coverage: 137 bars · Jun 23, 2025 → Jan 6, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CureVac N.V. (CVAC) is a Healthcare stock with a market cap of $1.05B. The stock last traded around $4.66 and down 13.7% across the available one-year price window (Jun 23, 2025 → Jan 6, 2026). Baseline metrics include revenue growth of +895.5%, EPS growth of +161.0%, a dividend yield of 0.0%. What stands out right now is revenue +895.5%, EPS +161.0%, free cash flow +125.8% with operating margin 212.0% and ROIC 13.5%. Valuation already assumes a fairly strong business story at P/E 6.9 and price/sales 12.6. Stock Foundry combines CVAC price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
CVAC
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
CVAC Max Drawdown
-25.23%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for CVAC and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$48.9M
-52.5% YoY
FY Net Income
-$129.1M
+68.6% YoY
Free Cash Flow
$475.1M
+155.2% YoY
Revenue Growth
+895.5%
EPS Growth
+161.0%
Gross Margin
93.0%
Net Margin
182.1%
Income statement
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 535M | 54M | 67M | 103M | 49M |
| Gross Profit | 429M | -71M | -117M | -135M | 35M |
| Operating Income | 178M | -274M | -249M | -412M | -124M |
| EBITDA | 210M | -234M | -209M | -386M | -123M |
| Net Income | 162M | -260M | -249M | -412M | -129M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
EUR
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 482M | 402M | 496M | 811M | 1.3B |
| Total Assets | 803M | 788M | 860M | 1.2B | 1.5B |
| Total Liabilities | 106M | 271M | 327M | 470M | 800M |
| Shareholder Equity | 697M | 517M | 533M | 688M | 711M |
| Total Debt | 39M | 42M | 42M | 29M | 30M |
| Net Debt | -443M | -361M | -454M | -783M | -1.3B |
Cash flow positioning
Latest Full Year
Operating Cash Flow
522M
+171.3% YoY
Capital Expenditures
47M
+63.0% YoY
Free Cash Flow
475M
+155.2% YoY
Key ratios
Gross Margin
93.0%
Operating Margin
212.0%
Net Margin
182.1%
ROE
18.4%
Debt / Equity
0.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.